ZTS 10-K Annual Reports

Zoetis Inc. reported solid financial results for the fiscal year ended December 31, 2025, with total revenue reaching $9.47 billion, a 2% increase year-over-year, driven by a 3% operational revenue growth. This growth was primarily attributed to price increases and contributions from key product franchises, partially offset by the impact of a divestiture. Net income grew 8% to $2.67 billion. The company continues to demonstrate strength in both its U.S. and International segments, with companion animal products representing a significant 70% of total revenue. Key product lines like Simparica/Simparica Trio and Apoquel/Apoquel Chewable remain strong contributors, accounting for a substantial portion of overall revenue. Zoetis also continues to invest in research and development, with expenses totaling $698 million, focusing on both new product development and lifecycle innovation. The company's balance sheet remains robust, with total assets growing to $15.47 billion. Zoetis actively manages its capital structure, including a significant share repurchase program of up to $6 billion, demonstrating a commitment to returning value to shareholders. The company's financial health is supported by a strong credit facility and diverse revenue streams across multiple species and product categories. Looking ahead, Zoetis is focused on its strategic pillars of innovation, customer experience, digital solutions, talent development, sustainability, and operational excellence to drive continued growth in the dynamic animal health market.

Zoetis Inc. reported strong financial performance for the fiscal year ended December 31, 2024, with total revenue reaching $9.26 billion, an increase of 8% year-over-year. This growth was driven by an 11% operational revenue increase, fueled by price adjustments (6%) and volume growth from new products and key dermatology products (3% and 2% respectively). The company's U.S. segment showed robust growth of 11%, while the International segment experienced a 5% increase in revenue, partially impacted by unfavorable foreign exchange. Companion animal products continue to be the primary revenue driver, accounting for approximately 68% of total revenue, with livestock products making up 31%. The company's top-selling products, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, remain significant contributors to overall revenue. Zoetis demonstrated effective cost management, with cost of sales as a percentage of revenue decreasing to 29.4% due to price increases, favorable product mix, and lower inventory and freight costs. Selling, general, and administrative expenses also saw an 8% increase, largely attributed to investments in compensation, selling, and promotional activities. Research and development expenses grew by 12%, reflecting continued investment in innovation and portfolio progression. The company also completed the divestiture of its medicated feed additive product portfolio in October 2024, which will impact future revenue streams. Zoetis remains committed to returning value to shareholders, evidenced by its completed $3.5 billion share repurchase program and a new $6 billion authorization, underscoring confidence in its future performance.

Zoetis Inc. (ZTS) reported a solid performance in its 2023 10-K filing, demonstrating consistent revenue growth driven by both price increases and volume from new products. The company maintains a diversified portfolio across companion animal and livestock segments, with companion animal products representing a larger portion of revenue. Key therapeutic areas like parasiticides, dermatology, and vaccines continue to be strong contributors. Zoetis's strategic focus on innovation, customer experience, and digital solutions is evident in its R&D investments and product lifecycle management. The company also highlighted its commitment to sustainability and employee well-being, reflected in its human capital management initiatives and decreasing voluntary attrition rate. Despite some challenges like supply chain constraints and increasing competition, Zoetis's financial health remains robust, supported by strong operating cash flow and a healthy balance sheet, allowing for continued investment in growth and shareholder returns through share repurchases and dividends.

Zoetis Inc. reported robust financial performance for the fiscal year ended December 31, 2022. The company achieved a 4% increase in total revenue, reaching $8.08 billion, driven by strong operational growth, particularly in companion animal products. Key drivers included volume growth from new products and price increases, with notable contributions from its dermatology portfolio. The company demonstrated resilience despite global economic challenges and supply chain headwinds experienced by some products. Zoetis continues to invest in research and development to fuel innovation and expand its diverse product lines across companion animals and livestock, positioning itself for sustained future growth. The company's strategic focus on driving innovative growth, enhancing customer experience, and leading in digital and data analytics appears to be yielding positive results. The U.S. segment saw a 7% revenue increase, while the International segment experienced a 1% rise, with operational growth offsetting foreign currency impacts. Zoetis also maintained a strong financial position with substantial cash reserves and access to credit facilities, enabling continued investment and shareholder returns through its share repurchase program.

Zoetis Inc. reported strong performance in its 2021 10-K filing, showcasing robust revenue growth driven by both its U.S. and International segments. The company's diversified portfolio, with a significant contribution from companion animal products (60% of revenue), highlights its resilience and market leadership in the animal health sector. Key growth drivers include increasing pet ownership, rising demand for quality animal protein, and the company's continuous innovation in medicines and vaccines. Zoetis's financial health appears solid, with significant cash reserves and manageable debt, supporting its ongoing investments in research and development and strategic acquisitions to further expand its offerings in diagnostics, precision animal health, and digital solutions. Despite the positive financial outlook, investors should be aware of the competitive landscape and potential risks, including patent expirations for certain key products and the ongoing impact of global economic conditions and regulatory changes. The company's strategic focus on innovation, customer experience, digital leadership, and sustainability positions it well for future growth, making it an attractive prospect for long-term investors in the animal health industry.

Zoetis Inc. reported robust performance for the fiscal year ended December 31, 2020, with total revenue reaching $6.68 billion, a 7% increase year-over-year. This growth was primarily driven by strong performance in companion animal products, which saw a 16% increase in revenue, and a 3% operational revenue growth in international markets. The company's financial health remained solid, supported by healthy operating cash flows. Zoetis continues to invest significantly in research and development, allocating $463 million in 2020 to drive innovation and expand its product lifecycle. Key product lines like Apoquel and the Simparica franchise demonstrated strong revenue contribution, underscoring the company's focus on high-demand therapeutic areas. Despite facing economic uncertainties and the ongoing impact of COVID-19, Zoetis maintained its market leadership position in the animal health industry.

Zoetis Inc.'s 2019 10-K report details a robust year of growth and strategic development in the animal health sector. The company demonstrated strong revenue performance, driven by both its established product lines and new product introductions, particularly in the companion animal segment. Key acquisitions, such as Abaxis, were integrated, contributing to expanded diagnostic capabilities and overall revenue. Zoetis continues to invest significantly in research and development, focusing on product lifecycle innovation and novel solutions for both livestock and companion animals. The company operates across two main segments: the U.S. and International, with each contributing significantly to overall revenue. Zoetis maintains a diversified product portfolio addressing a wide range of animal health needs, from vaccines and parasiticides to anti-infectives and diagnostics. The company's financial health appears solid, with consistent revenue growth and effective management of expenses, though it faces ongoing competitive pressures and the lifecycle management of key products. Investors can find confidence in Zoetis's market leadership, commitment to innovation, and strong financial discipline. The company's focus on expanding its product offerings, entering new markets, and enhancing customer experience positions it well for continued growth in the dynamic animal health industry. Key risks include patent expirations, competition, regulatory changes, and global economic uncertainties, all of which are actively managed by the company.

Zoetis Inc. reported strong financial performance for the fiscal year ended December 31, 2018, with total revenue reaching $5.825 billion, a 10% increase year-over-year. This growth was driven by a balanced performance across both its U.S. and International segments, with revenues of $2.877 billion and $2.890 billion, respectively. The company saw robust growth in its companion animal segment, up 17% to $2.613 billion, largely attributed to its key dermatology products and the strategic acquisition of Abaxis. The livestock segment also contributed positively, growing 4% to $3.154 billion, benefiting from demand for alternatives to antibiotic medicated feed additives and new product introductions. Net income attributable to Zoetis was $1.428 billion, a significant 65% increase from the previous year, bolstered by strong revenue growth and improved operational efficiencies. The company also benefited from a lower effective tax rate in 2018, following the enactment of the Tax Cuts and Jobs Act, which reduced the U.S. federal corporate tax rate. Zoetis continued its commitment to shareholder returns through share repurchases, authorizing an additional $2.0 billion, indicating confidence in its ongoing business strategy and future prospects.

Zoetis Inc. reported strong performance in its 2017 10-K filing, showcasing robust revenue growth driven by both its U.S. and International segments. The company's strategic focus on product innovation and lifecycle management, particularly in key product lines like Apoquel® and the ceftiofur line, has yielded positive results. Zoetis continues to invest in research and development to maintain its leadership in the animal health market. The company's operational efficiency program is largely complete, contributing to improved cost management. Financially, Zoetis demonstrated solid revenue growth and healthy net income. The company successfully managed its debt levels and continued its commitment to shareholder returns through dividends and share repurchases. While facing industry-wide challenges such as regulatory changes and competition, Zoetis' diversified portfolio across livestock and companion animals, coupled with its global reach, positions it well for continued success in the evolving animal health landscape.

Zoetis Inc.'s 2016 10-K report highlights a strong year of growth and strategic execution. The company, a global leader in animal health, reported total revenue of $4.89 billion, a 3% increase year-over-year, driven by operational revenue growth of 5%. This growth was primarily fueled by key product performance, including Apoquel, and contributions from recent acquisitions like Pharmaq. The company continues to balance investment in new product development with optimizing its existing portfolio and operational efficiency, as evidenced by its ongoing operational efficiency program. Zoetis operates in two key segments: the United States and International, with each contributing nearly half of the total revenue, showcasing a well-diversified geographic footprint. Financially, Zoetis demonstrated solid performance with net income attributable to Zoetis of $821 million, a significant increase from the prior year, supported by improved cost management and operational leverage. The company also managed its debt effectively and continued its commitment to shareholder returns through dividends and share repurchases. Key risks identified include regulatory changes regarding antibiotic use in livestock, increased competition, and global economic conditions, all of which the company is actively managing.

Zoetis Inc.'s 2015 10-K filing reveals a company that has successfully transitioned into an independent, global leader in animal health. For the year ended December 31, 2015, Zoetis reported total revenue of $4.765 billion, with a balanced contribution from its United States (49%) and International (50%) segments. The company demonstrates a strong product portfolio serving both livestock (62% of revenue) and companion animals (37% of revenue), with key product lines like ceftiofur, Revolution, and Draxxin contributing significantly to overall sales. Zoetis continues to invest in research and development, with $364 million allocated in 2015, focusing on both new product development and lifecycle innovation to maintain its competitive edge. The company also highlights its commitment to operational efficiency, with a program aimed at simplifying its product portfolio and optimizing its supply chain. Investors should note the company's strategic acquisitions, including Pharmaq for aquaculture and assets from Abbott Animal Health to bolster its companion animal offerings. While facing challenges such as foreign currency fluctuations (which negatively impacted revenue by 8% in 2015) and the ongoing global economic environment, Zoetis maintains a robust liquidity position and is focused on disciplined capital allocation and long-term value creation. The company also continues to manage its relationship with Pfizer through transitional services agreements, ensuring operational continuity.

Zoetis Inc. (ZTS) reported strong performance for the fiscal year ended December 31, 2014, marking its first full year as an independent public company following its separation from Pfizer in early 2013. The company demonstrated robust revenue growth of 5% year-over-year, reaching $4.79 billion, driven by solid operational performance across its global segments, particularly in the United States and emerging markets. This growth was fueled by both increased sales volume and price increases, supported by a diverse product portfolio targeting both livestock and companion animals. Key financial highlights include a 16% increase in Net Income Attributable to Zoetis, reaching $583 million. The company also reported a strong adjusted net income of $790 million, indicating effective management of operational costs and strategic investments in research and development. Zoetis's strategic focus on expanding its presence in emerging markets and developing new products, coupled with its established market leadership and customer relationships, positions it well for continued growth. The company's diversified revenue streams and focus on innovation in animal health medicine and vaccines present a stable and promising outlook for investors.

Zoetis Inc. (ZTS) has filed its 2013 Annual Report on Form 10-K, detailing its performance and strategic positioning as a newly independent entity following its separation from Pfizer Inc. The company is a global leader in animal health, focusing on the discovery, development, manufacture, and commercialization of medicines and vaccines for both livestock and companion animals. In 2013, Zoetis reported total revenue of $4.56 billion, a 5% increase driven by operational growth across all segments, despite a 2% unfavorable impact from foreign exchange. The U.S. segment remains the largest contributor to revenue at 42%. The company emphasizes its strong R&D capabilities, with a focus on product lifecycle development, and its extensive sales and marketing infrastructure, which allows for deep customer relationships. Key product lines like ceftiofur, Revolution, and Draxxin contribute significantly to revenue. The report also highlights the company's financial restructuring, including a $3.65 billion senior notes offering, and outlines strategies for future growth centered on emerging markets, innovation, and customer engagement.

Zoetis Inc., a global leader in animal health, officially separated from Pfizer Inc. in early 2013, completing an initial public offering (IPO) of its Class A common stock on the NYSE under the ticker "ZTS." The company's core business revolves around the discovery, development, manufacturing, and commercialization of medicines and vaccines for both livestock and companion animals. Zoetis operates across four geographic segments: the United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific, with international operations contributing 59% of its total revenues in 2012. The company's product portfolio spans five major categories: anti-infectives, vaccines, parasiticides, medicated feed additives, and other pharmaceutical products. Livestock products represented 65% of 2012 revenues, driven by global population growth and increasing demand for animal protein, while companion animal products accounted for 35%, benefiting from increased pet ownership and longer lifespans for pets. Zoetis emphasizes brand lifecycle development and new product R&D, with a significant investment in innovation. Key financial highlights for 2012 included revenues of $4.336 billion and a net income of $436 million.